Results 31 to 40 of about 2,223,573 (201)

Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway

Journal of Experimental & Clinical Cancer Research, 2019
Background Drug resistance is common in cancer chemotherapy. This study investigates the role of Glycerol kinase 5 (GK5) in mediating gefitinib resistance in NSCLC.
Jian Zhou, Guimei Qu, Ge Zhang, Zuoren Wu, Jing Liu, Dawei Yang, Jing Li, Meijia Chang, Hengshan Zeng, Jie Hu, Tao Fang, Yuanlin Song, Chunxue Bai   +12 more
doaj   +2 more sources

Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance

Toxicology and Applied Pharmacology, 2015
Gefitinib is the first-line chemotherapeutic drug for treating non-small cell lung cancer (NSCLC), which comprises nearly 85% of all lung cancer cases worldwide.
Chen, Jing-Ting, Lyu, Kevin W., Chan, Chia-Hao, Chou, Hsiu-Chuan, Lyu, Kevin W, Chung, Ting-Wen, Wu, Shin-Bei, Chan, Hong-Lin, Wen, Yueh-Feng, Lin, Chi-Chen, Lin, Meng-Wei   +10 more
core   +3 more sources

Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition. [PDF]

ACS Pharmacol Transl Sci, 2023
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) for treating advanced non-small cell lung cancer (NSCLC). However, drug resistance seriously impedes the clinical efficacy of gefitinib.
To KKW, Chow JCH, Cheung KM, Cho WCS.
europepmc   +2 more sources

Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance. [PDF]

Biomed Res Int, 2022
Met proto‐oncogene (MET) amplification and tyrosine‐protein kinase Met (c‐Met) overexpression confer gefitinib resistance in non‐small cell lung cancer (NSCLC). The natural product Licochalcone A (Lico A) exhibits a broad range of inhibitory effects against various tumors.
Han S, Li X, Gan Y, Li W.
europepmc   +3 more sources

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation

Frontiers in Pharmacology, 2021
Drug resistance can notably restrict clinical applications of gefitinib that is a commonly used EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC).
Yuhong Jiang, Xin Zhuo, Xiujuan Fu, Yue Wu, Canquan Mao   +4 more
doaj   +1 more source

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma. [PDF]

Transl Oncol, 2021
Lung adenocarcinoma patients with epidermal growth factor receptor (EGFR)-activating mutations respond well to tyrosine kinase inhibitors but typically develop resistance. Current therapies mainly target differentiated cells, not cancer stem cells (CSCs), but CSCs affect the occurrence, invasion, metastasis and treatment sensitivity of malignant ...
Yang H, Liu Y, Kong J.
europepmc   +4 more sources

Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells

Respiratory Research, 2021
Background Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been used as first-line treatment for advanced non-small-cell lung cancer (NSCLC). However, during treatment, cancer cells often develop resistance to gefitinib, the
Shaojia Wang, Chao Liu, Qing Lei, Zhengwei Wu, Xiangshuai Miao, Debing Zhu, Xu Yang, Na Li, Mingwei Tang, Yan Chen, Weiwei Wang   +10 more
doaj   +1 more source

Epithelial membrane protein-1 is a biomarker of gefitinib resistance [PDF]

Proceedings of the National Academy of Sciences, 2005
We describe a molecular resistance biomarker to gefitinib, epithelial membrane protein-1 (EMP-1). Gefitinib is a small-molecule inhibitor that competes for the ATP-binding site on EGF receptor (EGFR) and has been approved for patients with advanced lung cancers. Treatment with gefitinib has resulted in clinical benefit in patients,
Anjali, Jain, Charles A, Tindell, Isett, Laux, Jacob B, Hunter, John, Curran, Anna, Galkin, Daniel E, Afar, Nina, Aronson, Steven, Shak, Ronald B, Natale, David B, Agus   +10 more
openaire   +2 more sources

Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer

Cell Death Discovery, 2021
Patients with EGFR mutations in non-small cell lung cancer (NSCLC) have been greatly benefited from gefitinib, however, the therapeutic has failed due to the presence of acquired resistance.
Chuncao Xu, Lei Zhang, Daifei Wang, Shiqin Jiang, Di Cao, Zhongxiang Zhao, Min Huang, Jing Jin   +7 more
doaj   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source